Amarin (NASDAQ:AMRN) Given a $30.00 Price Target at Jefferies Financial Group

Jefferies Financial Group set a $30.00 price objective on Amarin (NASDAQ:AMRN) in a report released on Thursday, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on AMRN. Svb Leerink initiated coverage on Amarin in a research note on Wednesday, August 14th. They issued an outperform rating and a $26.00 price objective on the stock. Zacks Investment Research downgraded Amarin from a buy rating to a hold rating in a research report on Wednesday, July 24th. HC Wainwright restated a buy rating on shares of Amarin in a research report on Thursday, August 1st. Cantor Fitzgerald set a $35.00 target price on Amarin and gave the stock a buy rating in a research report on Tuesday, September 3rd. Finally, Stifel Nicolaus restated a buy rating and set a $26.00 target price on shares of Amarin in a research report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Amarin has an average rating of Buy and a consensus price target of $29.50.

Amarin stock traded down $0.04 during trading on Thursday, hitting $16.71. The stock had a trading volume of 5,046,988 shares, compared to its average volume of 6,368,218. Amarin has a 1 year low of $2.65 and a 1 year high of $23.91. The company has a quick ratio of 1.76, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average is $16.04 and its two-hundred day moving average is $18.41. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of -42.85 and a beta of 1.27.



Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. Amarin had a negative return on equity of 111.75% and a negative net margin of 27.51%. The business had revenue of $100.40 million for the quarter, compared to the consensus estimate of $99.54 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. Amarin’s revenue for the quarter was up 90.9% on a year-over-year basis. As a group, equities research analysts anticipate that Amarin will post -0.2 EPS for the current fiscal year.

In related news, CFO Michael Wayne Kalb sold 50,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $19.67, for a total value of $983,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lars Ekman sold 91,016 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total value of $1,366,150.16. Following the completion of the transaction, the director now directly owns 13,500 shares in the company, valued at approximately $202,635. The disclosure for this sale can be found here. In the last ninety days, insiders sold 659,202 shares of company stock worth $13,058,754. Insiders own 2.75% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wealthcare Advisory Partners LLC bought a new position in shares of Amarin during the first quarter valued at about $42,000. Kistler Tiffany Companies LLC grew its stake in shares of Amarin by 166.7% during the second quarter. Kistler Tiffany Companies LLC now owns 2,400 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 1,500 shares during the last quarter. Tobam grew its stake in shares of Amarin by 45.5% during the second quarter. Tobam now owns 3,200 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,000 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Amarin by 30.7% during the first quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 802 shares during the last quarter. Finally, Quantamental Technologies LLC bought a new position in shares of Amarin during the second quarter valued at about $74,000. 47.94% of the stock is currently owned by institutional investors and hedge funds.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Further Reading: What is the return on assets (ROA) ratio?

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.